Vaccine for KRAS-mutated advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new vaccine, ABO2102, for people with advanced solid tumors that have a specific change in the KRAS gene. The vaccine aims to help your immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- A genetic test must show your tumor has a KRAS mutation
- Your cancer must be advanced (spread) or locally advanced and cannot be removed by surgery
- Your tumor must be measurable on a scan
- You cannot have active brain metastases that need treatment
- You cannot have received a KRAS-targeted cancer vaccine before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial is testing a new mRNA vaccine (ABO2102) designed to target KRAS mutations in advanced solid tumors. It may be an option if your cancer has a KRAS mutation and standard treatments are no longer working.
This trial tests a new drug called ABSK211 in people with advanced solid tumors that have a change in the KRAS gene. The goal is to see if the drug is safe and works against the cancer.
This trial tests a personalized vaccine designed to train your immune system to fight any remaining cancer cells after surgery or during standard therapy. It is for people with solid tumors who are stable and have no signs of disease getting worse.
This trial tests a new type of cell therapy that uses your own immune cells, specially trained to attack cancer cells with a KRAS G12V or G12D mutation. It may be an option if you have advanced solid tumors that no longer respond to standard treatments.
This trial tests a personalized vaccine designed to target cancers with specific KRAS gene mutations. It may be an option for adults whose advanced solid tumor (like pancreatic or lung cancer) has not responded to standard treatments.
This trial tests a vaccine designed to target cancers with KRAS mutations. It may be an option if your cancer has a KRAS mutation and you have either tried other treatments without success or have a newly diagnosed, early-stage lung adenocarcinoma.
Hear when a new Advanced / Metastatic Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.